TY  - JOUR
AU  - Jiménez, Alberto
AU  - Ais, Arantza
AU  - Beaudet, Amélie
AU  - Gil, Alicia
PY  - 2018
DO  - 10.1186/s13023-018-0966-4
UR  - http://hdl.handle.net/10668/13294
T2  - Orphanet journal of rare diseases
AB  - Pulmonary Arterial Hypertension (PAH) is a chronic rare disease that can lead to serious cardiovascular problems and death. Additional treatments that increase effectiveness, that are safe and with a convenient administration that improve outcomes and...
LA  - en
KW  - Iloprost
KW  - MCDA
KW  - Multi-criteria decision analysis
KW  - Pulmonary arterial hypertension
KW  - Rare disease
KW  - Selexipag
KW  - Acetamides
KW  - Decision Making
KW  - Decision Support Techniques
KW  - Humans
KW  - Hypertension, Pulmonary
KW  - Pyrazines
KW  - Quality of Life
KW  - Rare Diseases
KW  - Spain
TI  - Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
TY  - research article
VL  - 13
ER  -